How many insider trades does FilingIQ track for CNTA?

FilingIQ tracks 379 Form 4 insider transactions for CNTA (Centessa Pharmaceuticals plc), covering filings from May 27, 2021 onwards. 24 of those were filed in the last 90 days.

Are CNTA insiders net buyers or net sellers?

Across the full Form 4 history for CNTA, 43 transactions (11%) were open-market purchases and 131 (35%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CNTA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CNTA in?

Centessa Pharmaceuticals plc (CNTA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.60B.

CNTA insider trading

Healthcare

Centessa Pharmaceuticals plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

379

Last 90 days

Buys / sells

11% / 35%

Market cap

$3.60B

About Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Company website: centessa.com

CNTA insider activity at a glance

FilingIQ has scored 379 insider transactions for CNTA since May 27, 2021. The most recent filing in our index is dated Mar 26, 2026.

Across the full history, 43 open-market purchases and 131 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CNTA insider trades is 54.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CNTA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding CNTA

Avoro Capital Advisors LLC

$364.03M · 3.6% of AUM

PERCEPTIVE ADVISORS LLC

$43.72M · 1.5% of AUM

Siren, L.L.C.

$42.57M · 2.4% of AUM

Samsara BioCapital, LLC

$6.52M · 1.3% of AUM

Exome Asset Management LLC

$2.19M · 1.6% of AUM

Frequently asked

How many insider trades does FilingIQ track for CNTA?: FilingIQ tracks 379 Form 4 insider transactions for CNTA (Centessa Pharmaceuticals plc), covering filings from May 27, 2021 onwards. 24 of those were filed in the last 90 days.
Are CNTA insiders net buyers or net sellers?: Across the full Form 4 history for CNTA, 43 transactions (11%) were open-market purchases and 131 (35%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CNTA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CNTA in?: Centessa Pharmaceuticals plc (CNTA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.60B.

Methodology & sources

Every CNTA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.